This top neuroscience news video summary covers Pier 88 Health & Theranica’s launch of the Nerivio® migraine device in China, Anavex Life Sciences’ new daily oral Alzheimer’s therapy, Alzheimer’s blood test advances from C2N Diagnostics and Roche & Eli Lilly, BioNxt’s MS therapy patent, Zenas BioPharma & InnoCare’s BTK inhibitor partnership, Immunic’s Phase III MS trial, and the WHO–Lilly collaboration to improve global dementia care.
Watch Our Video Summary Capturing Neuroscience News from the Last Two Weeks
🧠 Pier 88 Health & Theranica: Nerivio® Wearable Approved for Drug-Free Migraine Treatment in China [1] [China • 03 Oct 2025]
Context: Pier 88 Health and Theranica announce that the Nerivio® REN wearable device, a smartphone-controlled, drug-free migraine treatment, has received approval from China’s National Medical Products Administration.
Key point: This is the first approved wearable migraine device using Remote Electrical Neuromodulation (REN) technology in China, offering an alternative to traditional oral medications.
Implication: With over 130 million people affected by migraines in China, the device could significantly reduce reliance on oral treatments and prevent migraine chronification.
💊 Anavex Life Sciences: ANAVEX®3-71 Once-Daily Oral Tablet Formulation [2] [US • 02 Oct 2025]
Context: Anavex Life Sciences announces the development of a once-daily oral tablet for ANAVEX®3-71, a potential treatment for Alzheimer’s and other neurodegenerative diseases.
Key point: The modified-release formulation achieved superior pharmacokinetics in Phase 1b trials, supporting the transition to once-daily dosing.
Implication: This advancement could make the treatment more convenient for patients, improving adherence and offering a potential breakthrough in neurodegenerative disease therapies.
🧪 C2N Diagnostics: Alzheimer’s Blood Test Submitted for FDA Approval [3] [US • 01 Oct 2025]
Context: C2N Diagnostics submits its novel Alzheimer’s blood test for FDA approval, designed to detect amyloid pathology with high precision using high-resolution mass spectrometry (HRMS).
Key point: The multi-analyte test uses proprietary algorithms to quantify plasma amyloid and tau peptides, offering an easy, non-invasive diagnostic option for Alzheimer’s.
Implication: If approved, this test could revolutionize Alzheimer’s diagnosis, improving accessibility and reducing the reliance on expensive or invasive procedures like PET scans or spinal taps.
🩸 Roche & Eli Lilly: FDA Approves Elecsys Blood Test for Alzheimer’s [4] [US • 13 Oct 2025]
Context: Roche, in partnership with Eli Lilly, has received FDA approval for the Elecsys test, which measures pTau181, a protein associated with Alzheimer’s disease.
Key point: The test is intended for individuals aged 55 and older showing signs of cognitive decline, with a 97.9% negative predictive value in ruling out Alzheimer’s.
Implication: This marks a significant step forward in Alzheimer’s diagnostics, offering a quick, accessible, and less invasive alternative to traditional methods.
🏥 BioNxt Solutions: Fast-Track US Patent Filing for Sublingual Cladribine [5] [US • 09 Oct 2025]
Context: BioNxt Solutions has completed a fast-track patent filing for its sublingual thin-film cladribine formulation (BNT23001) for multiple sclerosis (MS).
Key point: The sublingual formulation aims to improve drug bioavailability and patient compliance compared to traditional tablets and injections.
Implication: This development could provide a more patient-friendly MS treatment, especially for individuals with swallowing difficulties or those seeking non-invasive alternatives.
🧬 Zenas BioPharma & InnoCare Pharma: Orelabrutinib License for MS [6] [08 Oct 2025]
https://www.globenewswire.com/news-release/2025/10/08/3163133/0/en/Zenas-BioPharma-and-InnoCare-Pharma-Announce-License-Agreement-Granting-Zenas-Rights-for-Three-Autoimmune-Product-Candidates-Including-Orelabrutinib-a-BTK-Inhibitor-in-Phase-3-Deve.html
Context: Zenas BioPharma has secured a license agreement for Orelabrutinib, a Phase 3 BTK inhibitor, for the treatment of progressive forms of MS.
Key point: Orelabrutinib is a highly selective CNS-penetrant BTK inhibitor showing promising results in Phase 2 trials.
Implication: This agreement provides Zenas with a strong asset for treating Primary and Secondary Progressive MS, where there is a significant unmet need for effective disease-modifying therapies.
💡 Immunic Therapeutics: Vidofludimus Calcium for Neuroprotection in MS [7] [06 Oct 2025]
Context: Immunic Therapeutics progresses vidofludimus calcium through Phase III trials, a treatment that activates Nurr1 to promote neuroprotection in MS.
Key point: The compound demonstrated efficacy in reducing disability progression in primary progressive MS (PPMS) and other progressive forms of MS in Phase II trials.
Implication: If successful, vidofludimus calcium could represent a novel class of neuroprotective treatments for progressive MS, which has limited therapeutic options.
WHO Foundation & Lilly Collaborate to Improve Global Dementia Care 🌍 [Germany • 13 Oct 2025]
Context: The WHO Foundation and Eli Lilly have joined forces to support the WHO’s Global Action Plan on dementia care. The initiative aims to improve access to dementia diagnostics, treatment, and care, particularly in low- and middle-income countries.
Key point: The collaboration focuses on enhancing early detection, improving care frameworks, and expanding access to services for those living with dementia.
Implication: This partnership could have a transformative impact on global dementia care, offering more equitable solutions and improving the lives of millions affected by Alzheimer’s and other dementias worldwide.
Why It Matters
• Pier 88 Health & Theranica’s Nerivio® wearable positions itself as a leading non-pharmacological treatment for migraines in China, filling a gap in the market for drug-free migraine therapies.
• Anavex Life Sciences’ once-daily ANAVEX®3-71 formulation offers a more patient-friendly alternative to conventional treatments for Alzheimer’s and neurodegenerative diseases, improving patient compliance.
• C2N Diagnostics’ Alzheimer’s blood test could streamline diagnostics, making early detection of Alzheimer’s more accessible and cost-effective.
• Roche & Eli Lilly’s Elecsys test further establishes the importance of blood-based diagnostics in Alzheimer’s disease, offering a reliable and efficient alternative to more invasive tests.
• BioNxt’s sublingual cladribine formulation has the potential to change the landscape of MS treatment by enhancing patient adherence and treatment efficacy.
• Zenas BioPharma’s Orelabrutinib represents a promising disease-modifying treatment for progressive MS, addressing a critical need for more effective therapies in this space.
• Immunic’s vidofludimus calcium may pave the way for neuroprotective therapies that go beyond symptom management, targeting the root causes of neurodegeneration in MS.
• WHO Foundation & Lilly’s dementia collaboration is a major step toward closing gaps in dementia care and expanding access to diagnosis and treatment, particularly in underserved regions.
🚀 Partner with LucidQuest to accelerate your success.
🧭 Explore our full range of services
💡 See our work across across multiple therapy area projects.
FAQ
What does Pier 88 Health’s Nerivio® wearable do?
The Nerivio® wearable is a drug-free migraine treatment device approved in China, offering a smartphone-controlled solution for both acute and preventive migraine care [4].
How does Anavex Life Sciences’ ANAVEX®3-71 oral tablet differ from other treatments?
The new once-daily oral tablet formulation of ANAVEX®3-71 enhances patient adherence and offers a more convenient option for treating Alzheimer’s and other neurodegenerative diseases [2].
What is the significance of C2N Diagnostics’ Alzheimer’s blood test?
C2N’s test uses mass spectrometry to detect amyloid pathology in the blood, providing an accessible and non-invasive way to diagnose
Alzheimer’s, especially for early-stage patients [3].
How does Zenas BioPharma’s Orelabrutinib work for MS?
Orelabrutinib is a BTK inhibitor that penetrates the CNS and modulates immune response, showing promise for progressive MS, a form of the disease with limited treatment options [6].
What is Immunic Therapeutics’ approach to MS?
Immunic’s vidofludimus calcium activates Nurr1, a protein that protects neurons, offering a neuroprotective strategy for MS that targets disease progression rather than just inflammation [7].
How will the WHO Foundation & Lilly collaboration impact dementia care?
This partnership aims to improve early detection, diagnosis, and care for dementia, especially in low- and middle-income countries, enhancing global access to treatments [8].
Entities / Keywords
Pier 88 Health; Theranica; Nerivio®; Anavex Life Sciences; ANAVEX®3-71; C2N Diagnostics; Alzheimer’s blood test; Roche; Eli Lilly; Elecsys; BioNxt Solutions; cladribine; Zenas BioPharma; Orelabrutinib; Immunic Therapeutics; vidofludimus calcium; progressive MS; Alzheimer’s disease; WHO Foundation; dementia care.
References
•